CVR number 25316460
Industry 86.2200 Specialist medical practice activities

SPECIALLÆGE ROLAND WELINDER ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  0.7% 0.7% 0.7% 0.7% 0.7%  
Bankruptcy risk  3.1% 1.9% 2.3% 2.2% 2.4%  
Credit score (0-100)  57 68 64 65 64  
Credit rating  BBB A BBB BBB BBB  
Credit limit (kDKK)  0.0 0.5 0.0 0.1 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  2,761 2,753 2,480 2,681 2,875  
EBITDA  991 488 276 477 670  
EBIT  925 423 210 412 564  
Pre-tax profit (PTP)  1,098.9 637.2 346.0 557.1 735.3  
Net earnings  894.8 541.4 309.5 459.2 585.2  
Pre-tax profit without non-rec. items  1,099 637 346 557 735  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  196 130 65.2 0.0 425  
Shareholders equity total  1,521 1,362 1,171 1,106 1,291  
Interest-bearing liabilities  59.2 34.5 28.5 33.1 9.0  
Balance sheet total (assets)  2,090 1,669 1,358 1,468 1,610  
Net Debt  -1,115 -598 -803 -883 -410  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,761 2,753 2,480 2,681 2,875  
Gross profit growth  6.5% -0.3% -9.9% 8.1% 7.2%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,090 1,669 1,358 1,468 1,610  
Balance sheet change%  22.4% -20.2% -18.7% 8.2% 9.6%  
Added value  990.6 488.4 275.7 476.9 670.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -130 -130 -130 -130 319  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  33.5% 15.4% 8.5% 15.4% 19.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  58.2% 34.3% 26.6% 38.7% 49.5%  
ROI %  77.2% 43.2% 31.0% 46.8% 62.4%  
ROE %  64.2% 37.6% 24.4% 40.3% 48.8%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  72.7% 81.6% 86.3% 75.3% 80.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -112.6% -122.5% -291.5% -185.1% -61.2%  
Gearing %  3.9% 2.5% 2.4% 3.0% 0.7%  
Net interest  0 0 0 0 0  
Financing costs %  23.0% 16.4% 179.6% -32.5% 129.4%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  2.9 4.0 5.5 3.5 3.1  
Current Ratio  2.9 4.0 5.5 3.5 3.1  
Cash and cash equivalent  1,174.6 633.0 832.0 915.6 419.4  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,075.1 628.3 596.3 544.7 248.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  991 488 276 477 670  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  991 488 276 477 670  
EBIT / employee  925 423 210 412 564  
Net earnings / employee  895 541 310 459 585